This inventor holds 3 USPTO granted patents and 2 EPO patents. Top assignee: Exelixis, Inc.. Active years: 2011-2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2011-2014
Title: Innovations of Bryan K S Yeung
Introduction
Bryan K S Yeung is a notable inventor based in Singapore, SG. He has made significant contributions to the field of biotechnology, particularly in the development of compounds that modulate protein kinase activity. With a total of 3 patents to his name, Yeung's work is pivotal in addressing kinase-dependent diseases.
Latest Patents
Yeung's latest patents include "Pyrazole kinase modulators and methods of use." This invention provides compounds that modulate protein kinase enzymatic activity, influencing cellular activities such as proliferation, differentiation, programmed cell death, migration, and chemoinvasion. The compounds are designed to inhibit, regulate, and modulate kinases, offering methods for treating various diseases and conditions. Another significant patent is "Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer." This invention focuses on compounds of Formula I and their pharmaceutically acceptable salts or solvates, along with methods for their production and application.
Career Highlights
Bryan K S Yeung is currently associated with Exelixis, Inc., where he continues to innovate in the field of cancer treatment and kinase modulation. His work is characterized by a strong emphasis on developing therapeutic solutions that can significantly impact patient care.
Collaborations
Yeung collaborates with esteemed colleagues such as Tae-Gon Baik and Chris Allen Buhr, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Bryan K S Yeung's contributions to biotechnology through his patents and collaborative efforts highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in the treatment of kinase-dependent diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
